Study of Tazemetostat in Lymphoid Malignancies

Status Not yet recruiting

Clinical Trial Summary

Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment option. We propose a study to evaluate the safety of tazemetostat in relapsed / refractory peripheral T-cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05983965
Study type	Interventional
Source	University of Alabama at Birmingham
Contact	Lauren Shea, MD
Phone	205-934-4793
Email	lkshea@uabmc.edu
Status	Not yet recruiting
Phase	Phase 1
Start date	May 2024
Completion date	December 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00959686` - Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma	Phase 2
Active, not recruiting	`NCT04712864` - Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma	Phase 1
Recruiting	`NCT05665530` - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies	Phase 1
Completed	`NCT01941680` - High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Recruiting	`NCT05075460` - Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma	Phase 3
Completed	`NCT03734601` - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation	Phase 2
Completed	`NCT02017613` - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies	Phase 1
Enrolling by invitation	`NCT01854112` - Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma	N/A
Completed	`NCT01553786` - Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)	Phase 2
Completed	`NCT00542919` - A Study for Patients With Non-Hodgkin's Lymphomas	Phase 2
Recruiting	`NCT06131801` - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Active, not recruiting	`NCT03952078` - A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma	Phase 1
Not yet recruiting	`NCT06390319` - Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)	Phase 2
Not yet recruiting	`NCT05387226` - Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma	Phase 1
Completed	`NCT02424045` - Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma	Phase 2
Completed	`NCT01871675` - Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies	Phase 1
Terminated	`NCT00893516` - CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma	Phase 2
Completed	`NCT01902225` - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma	Phase 1
Recruiting	`NCT02086591` - A Phase II Study of Doxycycline in Relapsed NHL	Phase 2
Recruiting	`NCT04264078` - Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies	Early Phase 1